Related Experiment Video

Updated: Feb 20, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

972

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat

Jui-Ting Chang1, Yao-Jen Liang2,3, Chia-Yu Hsu2

  • 1Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.

BMC Pharmacology & Toxicology
|October 26, 2017
PubMed
Abstract

Insights

Glucagon-like peptide-1 (GLP-1) receptor and peroxisome proliferator-activated receptor-delta (PPARδ) agonists reduce inflammation in advanced glycation end product-treated kidney cells. These agonists show potential in managing diabetic nephropathy complications.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Advanced glycation end products (AGEs) and receptor for AGEs (RAGE) drive diabetic nephropathy.
  • Peroxisome proliferator-activated receptor-delta (PPARδ) agonists exhibit anti-RAGE effects.
  • PPARδ agonists stimulate glucagon-like peptide-1 (GLP-1) secretion.

Purpose of the Study:

  • Investigate the anti-inflammatory effects of GLP-1 receptor (exendin-4) and PPARδ (L-165,041) agonists.
  • Evaluate individual and synergistic actions in AGE-treated rat mesangial cells (RMC).

Main Methods:

  • Treated rat mesangial cells (RMC) with AGEs.
  • Administered exendin-4 (GLP-1 receptor agonist) and L-165,041 (PPARδ agonist).
  • Assessed IL-6, TNF-α production, RAGE expression, and cell death.

Main Results:

  • Both exendin-4 and L-165,041 significantly reduced AGE-induced IL-6, TNF-α, RAGE expression, and cell death.
  • Exendin-4 and L-165,041 demonstrated similar anti-inflammatory potency.
  • Synergistic inhibition of cytokine production observed, but not for RAGE expression or cell death.

Conclusions:

  • GLP-1 receptor and PPARδ agonists possess anti-inflammatory properties.
  • These agonists are effective against AGE-induced damage in rat mesangial cells.
  • Potential therapeutic targets for diabetic nephropathy.
Keywords:
Diabetic nephropathyGlucagon-like peptideMesangial cellPPAR deltaRage

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

992
A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.1K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
752
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
615
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
715
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
702